Multi-angle light scattering (MALS) technology plays a crucial role in monitoring molecular weight in downstream processes of protein therapeutics like monoclonal antibodies. By coupling MALS with preparative hydrophobic interaction chromatography (HIC), a real-time process monitoring system can effectively control aggregate levels during purification. This technology offers two main applications: in-line MALS for instant feedback-triggered fractionation and on-line ultra-high performance size-exclusion liquid chromatography for continuous monitoring and confirmation of molecular weight. The ability to monitor and control protein aggregation in real time enables efficient biologics purification and paves the way for potential real-time release of biotherapeutics.
Proteins, especially when used as drugs, are prone to aggregation, which can compromise their quality, safety, and efficacy. Aggregation can occur at various stages of protein production and is influenced by different stress conditions. As aggregate levels are critical quality attributes, downstream purification operations are essential for removing these impurities. While Protein A affinity chromatography is effective in reducing host cell proteins and DNA, further purification steps like ion exchange chromatography, size-exclusion chromatography, and HIC are necessary to decrease aggregate levels. However, balancing aggregate removal with yield optimization is a key challenge in bioprocess development.
Implementing Process Analytical Technology (PAT) with MALS offers a significant advantage in assessing product quality during protein purification. The real-time monitoring of molecular weight using MALS provides immediate feedback for adjusting purification parameters, reducing the need for time-consuming offline analyses. By integrating MALS into the purification process, biopharmaceutical companies can enhance product quality, streamline process development, and potentially achieve real-time release of biotherapeutics. The use of MALS as a PAT tool aligns with regulatory expectations for building quality into pharmaceutical manufacturing processes.
The in-line MALS application enables automated real-time monitoring of molecular weight during the purification process, eliminating the need for post-processing analyses. By setting predetermined molecular weight criteria, the system can trigger fractionation events based on specific thresholds, optimizing the purification process and ensuring minimal aggregation in the final product. The on-line UHP-SEC-µMALS method complements the in-line MALS by providing accurate determination of aggregate species and their molecular weights. The integration of these technologies enables comprehensive monitoring and control of biologics purification steps, enhancing process efficiency and product quality.
The successful integration of MALS into bioprocess control offers numerous benefits, including improved process understanding, dynamic loading capabilities, and enhanced quality assurance. By utilizing real-time molecular weight measurements, biopharmaceutical companies can optimize purification steps, reduce processing time, and accelerate process development. As the industry continues to advance towards real-time release of biotherapeutics, technologies like in-line MALS play a crucial role in ensuring product quality and regulatory compliance. Through strategic integration of MALS as a PAT tool, companies can enhance process control, minimize risks, and drive innovation in bioprocess development.
Takeaways:
– Multi-angle light scattering (MALS) technology enables real-time monitoring of molecular weight in bioprocess control.
– Integrating MALS with downstream purification processes enhances product quality and streamlines process development.
– In-line MALS offers automated feedback-triggered fractionation, optimizing biologics purification in real time.
– On-line UHP-SEC-µMALS complements in-line MALS by providing accurate determination of aggregate species and molecular weights.
Tags: pharmaceutical manufacturing, cell culture, monoclonal antibodies, scale up, process analytical technology, downstream, process development, bioprocess, protein purification, formulation
Read more on pmc.ncbi.nlm.nih.gov